{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:12:18Z","timestamp":1769904738807,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1111\/igc.0b013e3181c14007","type":"journal-article","created":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T14:02:29Z","timestamp":1291384949000},"page":"S35-S39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"S2","title":["Consolidation Therapy in Ovarian Cancer"],"prefix":"10.1016","volume":"19","author":[{"given":"Paul","family":"Sabbatini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/IGC.0b013e3181c14007_bb0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0010","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1200\/JCO.2002.20.5.1238","article-title":"Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer","volume":"20","author":"Dizon","year":"2002","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0015","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0020","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.2005.04.5138","article-title":"Consolidation for ovarian cancer in remission","volume":"24","author":"Sabbatini","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0025","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0030","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bjc.6602037","article-title":"Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study","volume":"91","author":"Hall","year":"2004","journal-title":"Br J Cancer."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2005.07.117","article-title":"Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study","volume":"100","author":"Alberts","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1006\/gyno.2003.6882","article-title":"Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a Gynecologic Oncology Group study","volume":"88","author":"Schilder","year":"2003","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0045","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1200\/JCO.1993.11.3.440","article-title":"A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study","volume":"11","author":"Lambert","year":"1993","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0050","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/ijgc-00009577-200311001-00011","article-title":"Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy","volume":"13","author":"Sorbe","year":"2003","journal-title":"Int J Gynecol Cancer."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0055","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.2003.11.018","article-title":"Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group","volume":"21","author":"Varia","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0060","doi-asserted-by":"crossref","first-page":"116","DOI":"10.7150\/ijms.1.116","article-title":"A randomized study of epithelial ovarian cancer: is chemotherapy useful after complete remission?","volume":"1","author":"Nicoletto","year":"2004","journal-title":"Int J Med Sci."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0065","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1200\/JCO.2004.09.088","article-title":"Topotecan compared with no therapy after response to surgery and carboplatin\/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study","volume":"22","author":"De Placido","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0070","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","article-title":"Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial","volume":"21","author":"Markman","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0075","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2009.04.012","volume":"114","author":"Markman","year":"2009","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0080","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1200\/JCO.2004.12.043","article-title":"Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma","volume":"22","author":"Sabbatini","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0085","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1200\/JCO.2007.11.0775","article-title":"Immunologic approaches to ovarian cancer treatment","volume":"25","author":"Sabbatini","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0090","first-page":"223","article-title":"Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis","volume":"5","author":"Nicholson","year":"1998","journal-title":"Oncol Rep."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0095","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2005.02.5973","article-title":"Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission","volume":"24","author":"Verheijen","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0100","first-page":"187","article-title":"Induction of CA125-specific B and T cell responses in patients injected with MAb-B43. 13Vevidence for antibody-mediated antigen-processing and presentation of CA125 in vivo","volume":"16","author":"Noujaim","year":"2001","journal-title":"Cancer Biother Radiopharm."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0105","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1200\/JCO.2003.01.517","article-title":"Biologic and immunologic therapies for ovarian cancer","volume":"21","author":"Berek","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0110","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1089\/hyb.1993.12.583","article-title":"Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13","volume":"12","author":"Baum","year":"1993","journal-title":"Hybridoma."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0115","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/ijgc-00009577-200511000-00004","article-title":"A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer","volume":"15","author":"Ehlen","year":"2005","journal-title":"Int J Gynecol Cancer."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0120","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1067\/mob.2003.347","article-title":"Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer","volume":"189","author":"Mobus","year":"2003","journal-title":"Am J Obstet Gynecol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0125","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1200\/JCO.2004.09.016","article-title":"Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer","volume":"22","author":"Berek","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0130","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2008.17.8400","article-title":"Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer","volume":"27","author":"Berek","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0135","first-page":"1112","volume":"7","author":"Foon","year":"2001","journal-title":"Clin Cancer Res."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0140","first-page":"171","article-title":"Speculations on idiotypes of homobodies","volume":"124","author":"Lindemann","year":"1973","journal-title":"Ann Immunol (Paris)."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0145","first-page":"373","article-title":"Towards a network theory of the immune system","volume":"125","author":"Jerne","year":"1974","journal-title":"Ann Immunol (Paris)."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0150","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00002371-199809000-00006","article-title":"Immunologic response to the dual murine anti-Id vaccine Melimmune-1 and Melimmune-2 in patients with high risk melanoma without evidence of systemic disease","volume":"21","author":"Saleh","year":"1998","journal-title":"J Immunother."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0155","first-page":"1154","volume":"7","author":"Wagner","year":"2001","journal-title":"Clin Cancer Res."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0160","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0165","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0170","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0175","doi-asserted-by":"crossref","first-page":"7781","DOI":"10.1158\/1078-0432.CCR-08-0243","article-title":"Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model","volume":"14","author":"Mabuchi","year":"2008","journal-title":"Clin Cancer Res."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0180","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ygyno.2007.05.008","article-title":"Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials","volume":"106","author":"Harrison","year":"2007","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0185","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0190","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0195","first-page":"568","article-title":"A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission","volume":"29","author":"Juretzka","year":"2008","journal-title":"Eur J Gynaecol Oncol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0200","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/cncr.23072","article-title":"A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission","volume":"110","author":"Levine","year":"2007","journal-title":"Cancer."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0205","doi-asserted-by":"crossref","first-page":"R238","DOI":"10.1016\/j.cub.2008.01.050","article-title":"Hedgehog signalling","volume":"18","author":"Ingham","year":"2008","journal-title":"Curr Biol."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0210","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1158\/1078-0432.CCR-08-1414","article-title":"Role of hedgehog signaling in ovarian cancer","volume":"14","author":"Bhattacharya","year":"2008","journal-title":"Clin Cancer Res."},{"key":"10.1111\/IGC.0b013e3181c14007_bb0215","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1349-7006.2006.00353.x","article-title":"Hedgehog signal pathway is activated in ovarian carcinomas, correlating with cell proliferation: it\u2019s inhibition leads to growth suppression and apoptosis","volume":"98","author":"Chen","year":"2007","journal-title":"Cancer Sci."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2FIGC.0b013e3181c14007","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24155429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24155429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1111\/IGC.0b013e3181c14007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:17:17Z","timestamp":1753233437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24155429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":43,"alternative-id":["S1048891X24155429"],"URL":"https:\/\/doi.org\/10.1111\/igc.0b013e3181c14007","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consolidation Therapy in Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/IGC.0b013e3181c14007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2009 by IGCS and ESGO.","name":"copyright","label":"Copyright"}]}}